A phase III, randomised, double-blind, three-arm, placebo-controlled, multi-center study to evaluate the safety and efficacy of oral Cladribine in subjects with relapsing remitting multiple sclerosis To evaluate the efficacy of Cladribine versus Placebo in the reduction of qualifying relapse rate during 96 weeks of treatment in subjects with RRMS.

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A phase III, double-blind, placebo-controlled, randomised trial to determine the efficacy and safety of a dose range of 50 to 100 mg/day of safinamide, as add-on therapy, in subjects with idiopathic Parkinson’s Disease with motor fluctuations, treated with a stable dose of levodopa and who may be receiving concomitant treatment with stable doses of a dopamine agonist, an anticholinergic and/or amantadine The objectives of this trial are to evaluate the efficacy and safety of a dose range of safinamide 50-100 mg p.o. q.a.m., compared to placebo as add-on therapy in subjects with idiopathic Parkinson’s ...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A phase II, multicentre, randomised, assessor.blinded, active-comparator, parallel-group dose finding trial to evaluate AS900672-Enriched versus follitropin alfa (GONAL-f) in oligo-anovulatory infertile women undergoing ovulation induction (OI) The primary objective: Identify the optimal dose of AS900672- Enriched to induce ovulation in oligo-anovulatory infertile women.

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A multicentre, randomised, double blind, placebo controlled phase III study of subcutaneously administered onercept in the initial treatment and continued treatment after extended therapy in subjects with moderate to severe plaque psoriasis The primary objective is to assess the safety and efficacy of an initial 12-week treatment course with onercept 150 mg TIW for the induction of remission in patients with moderate to severe psoriasis,...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A multicentre, open label and subsequent randomised, double blind, placebo controlled phase III study to assess the safety and efficacy of maintenance and extended therapy with subcutaneously administered onercept of subjects with moderate to severe plaque psoriasis who have either responded or partially responded to an initial 12-week induction treatment with onercept The primary objective of the study is to assess the safety and efficacy of maintenance therapy with onercept 150 mg TIW compared to matching placebo in subjects having achieved a PASI 75 response at t...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A multicentre, open label Phase IIIb/IV study of subcutaneously administered efalizumab in the treatment of adult patients with moderate to severe chronic plaque psoriasis who have failed to respond to, or who have a contraindication to, or are intolerant of other systemic therapies including cyclosporin, methotrexate and PUVA To establish control of moderate to severe chronic plaque psoriasis with efalizumab in patients who have failed to respond to, or who have a contraindication to, or are intolerant to other systemic th...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Phase IV, one-day, single blood sampling study to investigate severe thrombocytopenia and autoimmune diseases in psoriasis subjects previously treated with RAPTIVA® (efalizumab) in the framework of the European Observational Safety Study 25878 (CLEAREST™) 1) To assess the prevalence of anti-efalizumab positivity in two sub-populations of psoriatic subjects treated with Raptiva® in the framework of the CLEAREST study: - Subjects developing adverse...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A phase IV open-label study of predictive markers in Growth Hormone Deficient and Turner Syndrome prepubertal children treated with Saizen To identify the most representative serum biomarkers after one month of Saizen therapy in Growth hormone deficiency (GHD) and Turner Syndrome (TS) children.

• Pays Aucun
• Organes Aucun
• Spécialités Aucune